Molecular imaging developer Gamma Medica has received a CE Mark for the sale and distribution of its LumaGem molecular breast imaging (MBI) system within the European economic area.
The company said it is finalizing distribution partners in strategic markets across the area.
MBI is a functional technique that highlights metabolic activity in the breast and detects tumors not visible on a mammogram due to tissue density. MBI may also be valuable for high-risk patients with a family history of breast cancer, patients who have tested positive for BRCA1 or BRCA2 genes, symptomatic patients, patients with cosmetic augmentation, or patients who cannot receive an MRI, according to the firm.
